Published: Sat, June 17, 2017
IT | By Jonathon Greene

Traders Purchase Large Volume of Apple Call Options (AAPL)

Traders Purchase Large Volume of Apple Call Options (AAPL)

A secretive team within Apple's growing health unit has been in conversations with developers, hospitals and other industry groups about consolidating all the clinical data like pathological reports and allergy lists into an iPhone.

Apple (AAPL) could surprise the world and make a move into the healthcare space by acquiring athenahealth (ATHN), Citi analyst Garen Sarafian suggested on Thursday.

"Essentially, Apple would be trying to recreate what it did with music - replacing CDs and scattered MP3s with a centralised management system in iTunes and the iPod - in the similarly fragmented and complicated landscape for health data", stresses CNBC's Christina Farr.

Although having all your medical history in one place could prove useful, do you really want a big business such as Apple to be able to know about all your health problems in intimate detail? But bringing a revolutionary health care feature to the iPhone, the most popular smartphone in the US, could make the company a heavy hitter in the industry immediately. An operation like this would give patients a full, easily accessible track of their health data, which they could then later share in full with a trusted doctor.

The Cupertino giant has been in the works to hire developers who are familiar with protocols dictating the transfer of electronic health records.

In the recent months, Apple has been in conversations with health IT industry groups that can help them achieve their goals. In 2011, Google shut down its Google Health due to a lack of traction.

A number of other large investors have also recently modified their holdings of AAPL.

This kind of tech always brings up the question of privacy when it comes to medical data. It has also made some notable hires from the medical sector of late, including a rising star of Stanford University's digital health efforts, Sumbul Desai, also reported by CNBC.

Apple did not respond to a Fortune request for comment on the CNBC report. BMO Capital Markets reaffirmed an "outperform" rating and set a $170.00 price objective (up from $160.00) on shares of Apple in a research report on Wednesday, May 17th.

Like this: